Low high-density lipoprotein cholesterol (HDL-C) levels are associated with incident
cardiovascular events; however, many therapies targeting increases in HDL-C have failed to …

Both alterations of lipid/lipoprotein metabolism and inflammatory events contribute to the
formation of the atherosclerotic plaque, characterized by the accumulation of abnormal …

Despite a robust inverse association between high-density lipoprotein (HDL) cholesterol
levels and atherosclerotic cardiovascular disease, the development of new therapies based …

Epidemiologic studies have shown an inverse correlation between high-density lipoprotein
(HDL) cholesterol (HDL-C) levels and cardiovascular disease outcomes. However, the …

Background It is unclear whether high-density lipoprotein (HDL) cholesterol concentration
plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux …

Reduction of low-density lipoprotein cholesterol by statin therapy has only modestly
decreased coronary heart disease (CHD)-associated mortality in developed countries …

Cardiovascular disease, with atherosclerosis as the major underlying factor, remains the
leading cause of death worldwide. It is well established that cholesterol ester-enriched foam …

CETP inhibitors raise HDL-C levels by 60–100% but in large event-driven randomized
controlled trials have either increased CV risk (torcetrapib), had no effect (dalcetrapib and …

Background High-density lipoprotein (HDL) may provide cardiovascular protection by
promoting reverse cholesterol transport from macrophages. We hypothesized that the …

A low plasma level of high-density lipoprotein (HDL) cholesterol (HDL-C) is a major risk
factor for the development of atherosclerotic cardiovascular disease (ASCVD). However …